Prot #PUMA-NER-1301: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/29/14 → 10/29/17

Funding

  • PSI Pharma Support America Inc. (Prot #PUMA-NER-1301)
  • Puma Biotechnology, Inc. (Prot #PUMA-NER-1301)